- |||||||||| CER-209 / Abionyx Pharma
Clinical, Observational data, Journal: Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer Attending the Tikur Anbessa Specialized Hospital, Addis Ababa Ethiopia, 2019: A Cross-sectional Study. (Pubmed Central) - Jun 22, 2021
In general, the overall adherence to AHT was 77.5% for women with breast cancer. Factors such as types of adjuvant hormone therapy, lack of side effects, mastectomy, getting social support, and thorough therapeutic communication were strongly linked with adherence to them.
- |||||||||| anastrozole / Generic mfg.
Clinical, Journal: Unusual case of long survival patient with leptomeningeal carcinomatosis from breast cancer. (Pubmed Central) - Jun 22, 2021
The patient was started on the aromatase inhibitor anastrozole...Although nowadays diagnosis of LC is prompted by cytological examination of CSF, its negativity should not halt the diagnostic process. In the presence of a high clinical suspicion of LC, we suggest the biopsy of lesion.
- |||||||||| Ibrance (palbociclib) / Pfizer
Enrollment closed: PATINA: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (clinicaltrials.gov) - Jun 15, 2021
P3, N=496, Active, not recruiting,
Higher awareness of BML cases and their molecular endocrinological features in the neurosurgical community may pave to develop better strategies for treatment of these tumors causing high morbidity. Recruiting --> Active, not recruiting
- |||||||||| letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Journal: Aromatase Inhibitors for the Treatment of Breast Cancer: A Journey from the Scratch. (Pubmed Central) - Jun 4, 2021
Sex Med 2021;XX:XXXXXX. AIs are the mainstream solution of ER+ breast cancer treatment regimen with the continuous improvement of human understanding of the importance of healthy life of women suffering from breast cancer.
- |||||||||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: DAWNA-2: A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Jun 2, 2021
P3, N=426, Active, not recruiting,
AIs are the mainstream solution of ER+ breast cancer treatment regimen with the continuous improvement of human understanding of the importance of healthy life of women suffering from breast cancer. Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2022
- |||||||||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Jun 2, 2021
P1/2, N=146, Active, not recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2022 Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2019 --> Dec 2021
- |||||||||| pictilisib (GDC-0941) / Roche, buparlisib (BKM120) / Novartis, Adlai Nortye
[VIRTUAL] Impact of PI3K inhibition in AIs-treated sensitive and resistant breast cancer cells: anti-proliferative effects and induction of apoptosis () - May 30, 2021 - Abstract #EACR2021EACR_1691;
The third-generation of aromatase inhibitors (AIs), anastrozole (Ana), letrozole (Let) and exemestane (Exe) are a first-line treatment option for estrogen receptor-positive (ER+ ) breast tumors, in postmenopausal women...Therefore, in this work the combinations of two PI3K class I inhibitors, buparlisib (BKM120) and pictilisib (GDC-0941), with AIs were explored in AIs-sensitive (MCF-7aro) and AIs-resistant (LTEDaro) breast cancer cell models...All the combinations in the resistant cells induced apoptosis, through mitochondrial pathway, with a more pronounced effect for the combinations with Exe. Conclusion Despite the high toxicity associated with the use of PI3K class I inhibitors, these results support further studies combining new, less toxic and specific PI3K class I inhibitors with AIs, especially with Exe, in refractory ER+ tumors The authors thank Fundação para a Ciência e Tecnologia (FCT) for T. Augusto PhD grant (BD/128333/2017) funded in part by FCT PhD Programme in Medicines and Pharmaceutical Innovation (i3DU), for C. Amaral contract (DL 57/2016 – Norma Transitória) and by Post-doc grant (SFRH/BPD/98304/2013) and for financial support (UIDP/04378/2020, UIDB/04378/2020).
- |||||||||| pictilisib (GDC-0941) / Roche, buparlisib (BKM120) / Novartis, Adlai Nortye
[VIRTUAL] Impact of PI3K inhibition in AIs-treated sensitive and resistant breast cancer cells: anti-proliferative effects and induction of apoptosis () - May 30, 2021 - Abstract #EACR2021EACR_1690;
The third-generation of aromatase inhibitors (AIs), anastrozole (Ana), letrozole (Let) and exemestane (Exe) are a first-line treatment option for estrogen receptor-positive (ER+ ) breast tumors, in postmenopausal women...Therefore, in this work the combinations of two PI3K class I inhibitors, buparlisib (BKM120) and pictilisib (GDC-0941), with AIs were explored in AIs-sensitive (MCF-7aro) and AIs-resistant (LTEDaro) breast cancer cell models...All the combinations in the resistant cells induced apoptosis, through mitochondrial pathway, with a more pronounced effect for the combinations with Exe. Conclusion Despite the high toxicity associated with the use of PI3K class I inhibitors, these results support further studies combining new, less toxic and specific PI3K class I inhibitors with AIs, especially with Exe, in refractory ER+ tumors The authors thank Fundação para a Ciência e Tecnologia (FCT) for T. Augusto PhD grant (BD/128333/2017) funded in part by FCT PhD Programme in Medicines and Pharmaceutical Innovation (i3DU), for C. Amaral contract (DL 57/2016 – Norma Transitória) and by Post-doc grant (SFRH/BPD/98304/2013) and for financial support (UIDP/04378/2020, UIDB/04378/2020).
- |||||||||| pictilisib (GDC-0941) / Roche, buparlisib (BKM120) / Novartis, Adlai Nortye
[VIRTUAL] Impact of PI3K inhibition in AIs-treated sensitive and resistant breast cancer cells: anti-proliferative effects and induction of apoptosis () - May 30, 2021 - Abstract #EACR2021EACR_1689;
The third-generation of aromatase inhibitors (AIs), anastrozole (Ana), letrozole (Let) and exemestane (Exe) are a first-line treatment option for estrogen receptor-positive (ER+ ) breast tumors, in postmenopausal women...Therefore, in this work the combinations of two PI3K class I inhibitors, buparlisib (BKM120) and pictilisib (GDC-0941), with AIs were explored in AIs-sensitive (MCF-7aro) and AIs-resistant (LTEDaro) breast cancer cell models...All the combinations in the resistant cells induced apoptosis, through mitochondrial pathway, with a more pronounced effect for the combinations with Exe. Conclusion Despite the high toxicity associated with the use of PI3K class I inhibitors, these results support further studies combining new, less toxic and specific PI3K class I inhibitors with AIs, especially with Exe, in refractory ER+ tumors The authors thank Fundação para a Ciência e Tecnologia (FCT) for T. Augusto PhD grant (BD/128333/2017) funded in part by FCT PhD Programme in Medicines and Pharmaceutical Innovation (i3DU), for C. Amaral contract (DL 57/2016 – Norma Transitória) and by Post-doc grant (SFRH/BPD/98304/2013) and for financial support (UIDP/04378/2020, UIDB/04378/2020).
- |||||||||| pictilisib (GDC-0941) / Roche, buparlisib (BKM120) / Novartis, Adlai Nortye
[VIRTUAL] Impact of PI3K inhibition in AIs-treated sensitive and resistant breast cancer cells: anti-proliferative effects and induction of apoptosis () - May 30, 2021 - Abstract #EACR2021EACR_1688;
The third-generation of aromatase inhibitors (AIs), anastrozole (Ana), letrozole (Let) and exemestane (Exe) are a first-line treatment option for estrogen receptor-positive (ER+ ) breast tumors, in postmenopausal women...Therefore, in this work the combinations of two PI3K class I inhibitors, buparlisib (BKM120) and pictilisib (GDC-0941), with AIs were explored in AIs-sensitive (MCF-7aro) and AIs-resistant (LTEDaro) breast cancer cell models...All the combinations in the resistant cells induced apoptosis, through mitochondrial pathway, with a more pronounced effect for the combinations with Exe. Conclusion Despite the high toxicity associated with the use of PI3K class I inhibitors, these results support further studies combining new, less toxic and specific PI3K class I inhibitors with AIs, especially with Exe, in refractory ER+ tumors The authors thank Fundação para a Ciência e Tecnologia (FCT) for T. Augusto PhD grant (BD/128333/2017) funded in part by FCT PhD Programme in Medicines and Pharmaceutical Innovation (i3DU), for C. Amaral contract (DL 57/2016 – Norma Transitória) and by Post-doc grant (SFRH/BPD/98304/2013) and for financial support (UIDP/04378/2020, UIDB/04378/2020).
- |||||||||| letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Review, Journal: Aromatase inhibitors: Role in postmenopausal breast cancer. (Pubmed Central) - May 21, 2021
It is, therefore, urgently required to develop novel anticancer drugs having better safety and efficacy for the treatment of breast cancer. This study highlights the aromatase inhibitors reported in the current literature as well as the recent advances in the management of breast cancer.
- |||||||||| anastrozole / Generic mfg.
Preclinical, Journal: 27-Hydroxycholesterol contributes to cognitive deficits in APP/PS1 transgenic mice through microbiota dysbiosis and intestinal barrier dysfunction. (Pubmed Central) - May 21, 2021
Although the successful implementation of the Medicare LIS program minimized the OOPCs for financially vulnerable patients, policymakers should be cautious not to introduce disparities for those who may be of low income but ineligible for such a program. The current study demonstrates for the first time that 27-OHC treatment aggravates AD-associated pathophysiological alterations, specifically gut microbiota dysbiosis and intestinal barrier dysfunction, which suggests that the gut microbiome and intestinal barrier function warrant further investigation as potential targets to mitigate the neurotoxic impact of 27-OHC on cognitive function and the development of AD.
- |||||||||| tamoxifen / Generic mfg.
Clinical, Journal: Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report. (Pubmed Central) - May 15, 2021
We offer the first reported use of tamoxifen monotherapy for the successful treatment of acromegaly and hormone-receptor-positive breast cancer. While tamoxifen may offer an additional, oral option for acromegaly patients who do not respond to or tolerate conventional growth-hormone-lowering therapy, additional studies are necessary.
- |||||||||| letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Review, Journal: MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers. (Pubmed Central) - May 14, 2021
Additionally, we discuss the potential effects of dysregulated miRNAs and lncRNAs on the regulation of critical oncogenic molecules, such as signal transducer, and activator of transcription 3, β-catenin, and integrins. The overall goal of this review is to stimulate further research in this area and to facilitate the development of ncRNA-based approaches for more efficacious treatments of ER-positive breast and ovarian cancer patients, with a slight emphasis on associated treatment-delivery mechanisms.
- |||||||||| Zarzio (filgrastim biosimilar) / Novartis
[VIRTUAL] DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN AN ADOLESCENT WITH SARS-COV-2 INFECTION () - May 13, 2021 - Abstract #EHA2021EHA_2121;
The adolescent boy had short stature and was rather overweighted for his age and gender (body mass index: 25.2 kg/m2), while over the last two years he was receiving anastrozole (aromatase inhibitor), for height increase...Initial management consisted of antibiotic therapy plus anticoagulation with subcutaneous low molecular weight heparin (LMWH) i.e. tinzaparin in therapeutic dose...He completed a ten-day course of intravenous dexamethasone and anticoagulation treatment was switched to oral warfarin, after completion of three weeks of LWMH...Conclusion This case underlines the fact that pediatric patients with COVID-19, are predisposed to the development of thromboembolic events, especially in the presence of preexisting prothrombotic risk factors. Larger studies in pediatric population with SARS-CoV-2 infection are needed, for the establishment of recommendations regarding risk evaluation, hemostatic monitoring and application of anticoagulation in outpatient, as well as hospitalized patients.
- |||||||||| Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases: Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (clinicaltrials.gov) - May 11, 2021
P2, N=327, Active, not recruiting,
These findings support holding these medications for 1 to 2 half lives (tamoxifen, 14-28 days; AIs, 2-4 days) preoperatively. Trial primary completion date: Mar 2021 --> Jun 2021
- |||||||||| tamoxifen / Generic mfg., fulvestrant / Generic mfg.
Clinical, Journal: Survival Outcomes of Early-Stage Hormone Receptor-Positive Breast Cancer in Elderly Women. (Pubmed Central) - May 5, 2021
Elderly breast cancer patients with early-stage hormone-receptor-positive disease receiving primary surgical intervention plus endocrine therapy may have significantly improved survival than those receiving primary endocrine therapy alone. This study suggests the importance of surgical intervention for elderly breast cancer patients and warrants further investigation and comprehensive geriatric assessment to identify subsets of elderly breast cancer patients who may benefit significantly from surgical intervention.
- |||||||||| Apristor (onapristone XR) / Context Therap
Trial completion date, Trial primary completion date, Combination therapy, Pan tumor: A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone (clinicaltrials.gov) - May 5, 2021
P2, N=84, Recruiting,
This study suggests the importance of surgical intervention for elderly breast cancer patients and warrants further investigation and comprehensive geriatric assessment to identify subsets of elderly breast cancer patients who may benefit significantly from surgical intervention. Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2021 --> Apr 2022
- |||||||||| Herceptin (trastuzumab) / Roche
[VIRTUAL] Amiodarone Induced Hallucinations: A Case Report () - May 2, 2021 - Abstract #APA2021APA_1028;
Her major depressive disorder and anxiety have remained in remission on a regimen of bupropion, duloxetine and trazodone without recent dose changes...For this reason, amiodarone was replaced with dronedarone...Isolated hallucinations have not been reported with amiodarone to the best of our knowledge. While the risk of visual and auditory hallucinations appears to be low with amiodarone initiation, we recommend that clinicians should be aware of this potential side effect.
|
